Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimodivir Pharmacokinetics in Hepatic Impairment
NCT03816631Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimodivir in Influenza A (IAV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration at Day 14, Area Under Concentration-Time Curve from Time 0 to Last Concentration at Day 14 and 1 more. Started May 2019; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03816631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816631.